Recent Advances and the Future Landscape of Genome Editing For Disease Models And How This Has Helped Us Gain Insight Into Disease Biology
In this video Q&A we discuss the recent advances in the landscape of genome editing for disease modelling. Topics include the developments in the genome editing landscape, the limitations and necessity of iPSC disease models, CRISPRi & CRISPRa for functional genomics and new insights gene editing has uncovered in disease biology.
Laralynne will be joining us again at Oxford Global’s NextGen Omics US: In-Person, as part of a 6th Annual Genome Editing Congress. She will be presenting in March on Next-Generation CRISPR Screening Platforms For Insights Into Human Disease Biology.
Speaker Biographies
Laralynne Przybyla, PhD, is an Adjunct Assistant Professor at UCSF and UC Scientific Director at the Laboratory for Genomics Research, a joint industry-academia hybrid institute between UCSF, UC Berkeley, and GSK. Her research has focused on cell and developmental biology, including building human iPSC-based models to uncover the molecular basis of developmental processes and disease states. Dr. Przybyla obtained her PhD in Biology from MIT and has experience leading technology development teams in both academia and industry. At the LGR, Laralynne leads the UC team to develop and implement new CRISPR-based functional genomics models, tools, and platforms, with the goal of creating and disseminating next-generation technologies and furthering our understanding of the mechanisms and genetics underlying human disease biology.Â
Â